Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Hemophilia Seen As Good Testing Ground For Commercializing Gene Therapy

Oct 09 2018

• By Mandy Jackson

3-D Rendering Red Blood Cells

Related Content

Hemophilia Gene Therapy Studies Could Use Non-Inferiority Design, US FDA Suggests

Jul 16 2018

Roche's Hemlibra Wins Expanded FDA Approval, Opening The Door To Broad Hemophilia A Opportunity

Oct 04 2018

Roche's Hemlibra Priced And Labeled To Beat Competition, Safety Concern

Nov 17 2017

BioMarin, Spark Hemophilia Gene Therapies Progress As Accelerated Approval Favors Their Indications

May 23 2018

Related Companies

Spark Therapeutics, Inc.

Pfizer Inc.

BioMarin Pharmaceutical Inc.

Sangamo Therapeutics, Inc.

uniQure N.V.

Roche Holding AG

Additional Topics

Regenerative Medicine Reimbursement Market Access Rare Diseases Commercial Blood & Coagulation Disorders BioPharmaceutical

More from Cell Therapies

More from Advanced Therapies

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.